Vertex, Inc.

Fundamentals5.0
Price Action5.0
News Sentiment7.0
AI Rating
6.0

Key Drivers

  • Recurring Revenue
  • Liquidity Squeeze
  • High Leverage

AI
AI Summary

6.0

VERX has shifted from a simple growth story to a prove-it name: the tax/compliance opportunity is real, but the stock now depends on management sustaining cloud conversion and EBITDA gains fast enough to offset weaker growth visibility and a still-fragile balance sheet.

CloudGrowth
BalanceSheet
ExecutionRisk‍

Price Chart

Loading chart...

Financial Metrics

-
Revenue (TTM)
-
Net Income (TTM)
-
EPS (Q)
-
MCAP

Deep Analysis

Research tool. Not personalized advice.

Fundamental Analysis

5.0

Key Financial Insights:

  • Recurring Revenue
  • Liquidity Squeeze
  • High Leverage

VERX has strong recurring-revenue quality and cash flow, but thin operating margins, weakening liquidity, high leverage, and a very rich earnings multiple make the stock risky despite a more reasonable sales-based valuation.

RecurringRevenue
BalanceSheetRisk

Price Behavior

5.0
Research tool. Not personalized advice. Technical analysis is for informational purposes only.

Key Price Behavior Insights:

  • Higher lows
  • Resistance zone
  • Cooling momentum

VERX's last month rebound remains constructive with higher lows and intact mid-$12 support, but repeated rejection near $13.25–$13.40 keeps the setup neutral until a breakout confirms.

VERX
neutral
Support Level: $12.00–$12.20
Resistance Level: $13.25–$13.40

Sharp rebound from the late-July low into early

Sentiment & News

7.0

Key News Insights:

  • EBITDA Raise
  • E-invoicing Demand
  • Diversification Push

Vertex, Inc. posted a Q2 beat and raised guidance on disciplined costs and e-invoicing demand, while Vertex Pharmaceuticals also lifted its outlook on solid franchise growth, though sustainability and competition remain key watchpoints.

growth
momentum

Overall, the news is supportive for both names, but further upside likely depends on continued execution and proof that growth can hold